TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04631081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coverage of the fingertips with bipedicled palmar island flap
Description: The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusive dressing
Description: patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
Study: NCT05222893

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory monitoring
Description: Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory monitoring
Description: Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
Study: NCT06445907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q702
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q702
Description: Given by PO
Study: NCT04680468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: 2.5 mg/kg IV
Study: NCT06482216

Intervention type: BIOLOGICAL
Intervention: Varicella vaccine
Description: lyophilized powder,subcutaneous injection
Study: NCT04319042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Loading
Description: The implant receives an artificial tooth the same day as it is placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Loading
Description: The implant receives an artificial tooth 4 weeks after placement.
Study: NCT06272942

Intervention type: OTHER
Intervention: An ICU admission and a temporally related ARDS diagnosis
Description: This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome.
Study: NCT05118295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVI Scout®
Description: Savi Scout marker is placed within 1 cm of the breast tumor
Study: NCT06050252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT04829877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based mind-body intervention with HRVB
Description: The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based mind-body intervention
Description: The web-based mind-body intervention will receive 5 different topics courses.
Study: NCT05564130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 1 mmol/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 9 mg/mL
Study: NCT06205381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV078
Description: Oral solution containing active ingredient, AV078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution with no active ingredients

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Once daily oral dose of 200 mg itraconazole administered for 9 days

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: 2.5 mg midazolam administered orally on day 1 and day 18

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: 120 mg fexofenadine administered orally on day 1 and day 18
Study: NCT05437978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cap Sport Santé 83 program
Description: In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator.
Study: NCT05045157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous A1 Pulley Release Under Ultrasound Guidance
Description: the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: corticosteroid injection is performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: corticosteroid injection is performed
Study: NCT04508309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cecolin®
Description: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cecolin®
Description: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cecolin®
Description: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cecolin®
Description: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil®
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
Study: NCT04960709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti- PD-L1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti- PD-L1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Human IgG2 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Nectin-4-directed antibody and microtubule inhibitor conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Nectin-4-directed antibody and microtubule inhibitor conjugate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: For cisplatin-ineligible or cisplatin-refusal patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: For cisplatin-ineligible or cisplatin-refusal patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: For cisplatin-ineligible or cisplatin-refusal patients
Study: NCT06121479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid
Description: Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
Study: NCT05622929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally-enabled Multifaceted Quality Improvement Intervention
Description: Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~* Knowledge of effective lipid lowering therapies~* Clinical decision support~* Audit and feedback on adherence to optimal clinical management~* Audit and feedback on LDL-C control

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
Study: NCT05509413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEFLAGYN vaginal gel
Description: DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
Study: NCT05172258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05222893

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: Measurement of the oxygen partial pressure and the carbon dioxide partial pressure

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: Measurement of the oxygen partial pressure and the carbon dioxide partial pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal pressure
Description: Measurement the pressure in the lower third of esophagus during inspiration and expiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal pressure
Description: Measurement the pressure in the lower third of esophagus during inspiration and expiration
Study: NCT05128474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Control-Based Exercise Training Group
Description: Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Training Group
Description: In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
Study: NCT05172258

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study: NCT06302829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramusuar electrical stimulation
Description: Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
Study: NCT06347549

Intervention type: DIAGNOSTIC_TEST
Intervention: Various intensities of inspiratory muscle training
Description: Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest.
Study: NCT06004453

Intervention type: OTHER
Intervention: Heart Failure medications
Description: There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.

Intervention type: OTHER
Intervention: Heart Failure medications
Description: There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.

Intervention type: OTHER
Intervention: Heart Failure medications
Description: There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.

Intervention type: OTHER
Intervention: Heart Failure medications
Description: There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.

Intervention type: OTHER
Intervention: Heart Failure medications
Description: There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
Study: NCT04731961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (15 Botox injections)
Description: The controls will be given the standard of care of 15 Botox injections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Arm (5 Botox injections)
Description: 5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
Study: NCT05845710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroguard IEP Direct System
Description: carotid artery stenting, direct access with blood flow redirection
Study: NCT04140734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer Graft
Description: In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer Graft
Description: In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer Graft
Description: In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
Study: NCT05012631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
Study: NCT05009979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-FDG
Description: Within approximately 2 weeks of each 18F-DCFPyL PET/CT scan, participants will be scanned with a 18F-FDG PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT
Description: A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-DCFPyL
Description: Each subject will receive a single IV dose of 18F-DCFPyL by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL PET/CT imaging will consist of the 18F-DCFPyL injection, followed by a approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/- 10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.